SML1629

Ezetimibe

≥98% (HPLC), Cholesterol absorption inhibitor, powder

• Synonim(y): (3R,4S)-1-(4-Fluorophenyl)-3-[(S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
• Wzór empiryczny (zapis Hilla): C₂₄H₂₁F₂NO₃
• Numer CAS: 163222-33-1
• Masa cząsteczkowa: 409.43
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825513
• NACRES: NA.77
• MDL number: MFCD00937872
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: Ezetimibe, ≥98% (HPLC)
• Quality Segment: 200
• assay: ≥98% (HPLC)
• form: powder
• solubility: DMF: soluble ≥15 mg/mL, DMSO: soluble ≥15 mg/mL, ethanol: soluble ≥15 mg/mL, methanol: soluble ≥15 mg/mL
• storage temp.: 2-8°C
• SMILES string: FC(C=C1)=CC=C1N([C@H](C2=CC=C(O)C=C2)[C@H]3CC[C@H](O)C4=CC=C(F)C=C4)C3=O
• InChI: 1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
• InChI key: OLNTVTPDXPETLC-XPWALMASSA-N

Opis

Biochem/physiol Actions

Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by Niemann-Pick C1 Like 1 (NPC1L1) protein that was found critical for the intestinal absorption of cholesterol. Ezetimibe selectvely blocks cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen.

Ezetimibe is a non statin drug that reduces intestinal cholesterol absorption. In addition, it also has an ability to reduce the risk of cardiovascular events in patients who had had an acute coronary syndrome and whose low-density lipoprotein (LDL) cholesterol values were within guideline recommendations.

Preparation Note

For solubility in aqueous buffer, Ezetimibe should be dissolved in ethanol followed by dilution with the buffer.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable